The Effect of Semaglutide on Pituitary Function

Sponsor
University of Tartu
Study ID
NCT04865744
Phase
PHASE4
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • Semaglutide 7 MG Oral Tablet — DRUG
    Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
  • Placebo — DRUG
    Placebo tablet is taken after an overnight fast with up to120 ml of water.
  • Semaglutide 14 MG Oral Tablet — DRUG
    Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.

Study Details

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

Key Dates

Start date
May 19, 2021
Status verified
Feb 2023
Primary completion
Sep 23, 2021
Completion
Sep 30, 2021

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC

Arms

  • Active Comparator: Oral semaglutide 7 mg
    The semaglutide 7 mg tablet taken orally with upto120 ml of water.
  • Placebo Comparator: Placebo
    The placebo tablet taken orally with 120 ml of water.
  • Active Comparator: Oral semaglutide 14 mg
    The semaglutide 14 mg tablet taken with upto 120 ml of water.

Primary Outcome Measure

Growth hormone peak [ Time Frame: 60, 90, 120, 150, 180 and 240 minutes after study medication administration ]

Related Studies